Dr. Andrew Piefer on Biochemistry
Dr. Elizabeth Bloom on Education
By Eric Cooper, Ph.D.
In September 2018, The New York Times reported on a successful preliminary clinical trial performed by scientists at the Boston based biotech company Synlogic. They used synthetic biology to “reprogram” the harmless bacteria that normally reside within us into a delivery system to provide a missing enzyme to individuals with the hereditary disease Phenylketonuria (PKU). This could usher in a new generation of novel therapies for improving people’s lives. Read more…
A molecular and cellular biologist, Associate Professor of Biology Cooper earned his Ph.D. from Harvard University.